MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
2.610
-0.220 (-7.77%)
At close: Mar 6, 2026, 4:00 PM EST
2.660
+0.050 (1.92%)
After-hours: Mar 6, 2026, 7:57 PM EST
MannKind Revenue
In the year 2025, MannKind had annual revenue of $348.97M with 22.23% growth. MannKind had revenue of $111.96M in the quarter ending December 31, 2025, with 45.82% growth.
Revenue (ttm)
$348.97M
Revenue Growth
+22.23%
P/S Ratio
2.30
Revenue / Employee
$589,470
Employees
592
Market Cap
804.14M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 348.97M | 63.46M | 22.23% |
| Dec 31, 2024 | 285.50M | 86.54M | 43.50% |
| Dec 31, 2023 | 198.96M | 99.19M | 99.42% |
| Dec 31, 2022 | 99.77M | 24.33M | 32.25% |
| Dec 31, 2021 | 75.44M | 10.30M | 15.81% |
| Dec 31, 2020 | 65.14M | 2.11M | 3.34% |
| Dec 31, 2019 | 63.04M | 35.18M | 126.28% |
| Dec 31, 2018 | 27.86M | 16.11M | 137.20% |
| Dec 31, 2017 | 11.75M | -163.01M | -93.28% |
| Dec 31, 2016 | 174.76M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xencor | 125.58M |
| CytomX Therapeutics | 113.63M |
| Kura Oncology | 67.48M |
| Evommune | 13.00M |
| KalVista Pharmaceuticals | 1.43M |
MNKD News
- 1 day ago - MannKind Announces Settlement of Convertible Senior Notes - GlobeNewsWire
- 2 days ago - MannKind to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 8 days ago - MannKind Corporation (MNKD) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 15 days ago - MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 16 days ago - MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire
- 25 days ago - MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D) - GlobeNewsWire
- 4 weeks ago - 2026 Outlook: Afrezza, Furoscix, And MannKind's Path To Revenue Expansion - Seeking Alpha